Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Equity Capital Markets

Beijing QL Biopharmaceutical / Equity Capital Markets

<ul>
<li>Beijing QL Biopharm, a China-based biopharmaceutical company, is looking to raise via a Hong Kong listing. Jefferies and Huatai are the joint sponsors.</li>
<li>In this note, we look at the company's one Phase III core product, zovaglutide (ZT002).</li>
<li>We also look at the company's pre-IPO investors and management team.</li>
</ul>


Beijing QL Biopharm, a China-based biopharmaceutical company, is looking to raise via a Hong Kong listing. Jefferies and Huatai are the joint sponsors.
In this note, we look at the company's one Phase III core product, zovaglutide (ZT002).
We also look at the company's pre-IPO investors and management team.


Imeik Technology Development C (300896 CH)

Beijing QL Biopharm (质肽生物医药) Pre-IPO: Monthly GLP-1 Convenience Needs a Stronger Efficacy Case